Plain-English translation of NCT03121001 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Sickle Cell Disease research guide โPhase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a stem cell transplant procedure for people with sickle cell disease who have serious complications like stroke, frequent pain crises, or lung problems. Instead of waiting for a perfectly matched donor (which many patients don't have), this study uses stem cells from a half-matched family member โ like a parent, sibling, or cousin. The goal is to see if this approach can help patients get better while being safer and more accessible than traditional transplants.
Most people with severe sickle cell disease don't have a perfectly matched bone marrow donor available, which limits their treatment options. This trial exists to find out whether using stem cells from a partially matched family member can work as an effective alternative, giving more patients access to potentially life-changing treatment.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will receive conditioning treatment with chemotherapy and low-dose radiation to prepare your body for the transplant, followed by infusion of stem cells from your matched family donor. After the transplant, you'll take medications to prevent rejection and receive follow-up evaluations at days 30, 60, 100, 180, 365, and then yearly. The study will monitor how well the transplanted cells take hold in your body and track your health over time.
AI-generated summary from trial data ยท Jul 15, 2026 ยท Not medical advice
United States